Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$73.50 -0.4%	$73.69	$62.75 ▼ $87.68	$227.94B	0.41	5.09 million shs	3.89 million shs
EXAS Exact Sciences	$43.29 -0.8%	$49.54	$40.62 ▼ $79.62	$8.04B	1.25	2.61 million shs	1.37 million shs
ILMN Illumina	$79.34 -0.8%	$101.65	$77.54 ▼ $156.66	$12.57B	1.17	2.20 million shs	1.74 million shs
MYGN Myriad Genetics	$8.87 -0.1%	$11.69	$8.53 ▼ $29.30	$810.82M	1.79	875,340 shs	1.10 million shs
NTRA Natera	$141.41 -1.8%	$159.26	$83.13 ▼ $183.00	$19.46B	1.8	1.36 million shs	2.30 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	-0.39%	-0.80%	-3.56%	+12.18%	+8.49%
EXAS Exact Sciences	-0.85%	-8.07%	-8.69%	-22.96%	-37.32%
ILMN Illumina	-0.82%	-9.86%	-10.59%	-40.63%	-42.22%
MYGN Myriad Genetics	-0.11%	-11.12%	-17.33%	-35.30%	-58.40%
NTRA Natera	-1.76%	-8.07%	-9.11%	-10.67%	+54.61%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	2.9836 of 5 stars	2.6	5.0	1.7	0.0	3.6	0.0	1.3
EXAS Exact Sciences	4.5503 of 5 stars	4.5	2.0	0.0	4.7	3.3	1.7	0.6
ILMN Illumina	4.7748 of 5 stars	4.2	5.0	0.0	4.2	2.8	1.7	1.3
MYGN Myriad Genetics	4.1179 of 5 stars	4.1	1.0	0.0	4.1	2.7	1.7	0.6
NTRA Natera	3.8148 of 5 stars	4.5	3.0	0.0	0.0	3.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	3.10	Buy	$89.75	22.11% Upside
EXAS Exact Sciences	2.90	Moderate Buy	$70.26	62.31% Upside
ILMN Illumina	2.48	Hold	$140.90	77.59% Upside
MYGN Myriad Genetics	2.20	Hold	$21.89	146.82% Upside
NTRA Natera	3.00	Buy	$178.12	25.96% Upside

Current Analyst Ratings Breakdown

Latest ILMN, NTRA, EXAS, MYGN, and AZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	EXAS Exact Sciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$60.00
3/13/2025	EXAS Exact Sciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$52.00
3/13/2025	NTRA Natera	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$251.00
3/12/2025	ILMN Illumina	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$247.00 ➝ $128.00
3/12/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$11.50 ➝ $12.50
3/12/2025	NTRA Natera	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
3/11/2025	ILMN Illumina	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
3/11/2025	ILMN Illumina	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$156.00 ➝ $156.00
3/11/2025	ILMN Illumina	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$135.00 ➝ $115.00
3/5/2025	ILMN Illumina	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$127.00 ➝ $90.00
3/5/2025	NTRA Natera	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$176.00 ➝ $185.00

(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.22	$6.23 per share	11.79	$13.18 per share	5.58
EXAS Exact Sciences	$2.76B	2.91	$4.92 per share	8.79	$12.93 per share	3.35
ILMN Illumina	$4.37B	2.87	$3.83 per share	20.72	$14.98 per share	5.30
MYGN Myriad Genetics	$837.60M	0.97	N/A	N/A	$9.53 per share	0.93
NTRA Natera	$1.70B	11.27	N/A	N/A	$6.37 per share	22.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.26	32.52	14.70	1.42	13.01%	32.23%	12.31%	4/24/2025 (Estimated)
EXAS Exact Sciences	-$204.15M	-$5.57	N/A	86.58	N/A	-37.29%	-5.29%	-2.45%	5/6/2025 (Estimated)
ILMN Illumina	-$1.22B	-$7.68	N/A	15.38	1.60	-27.95%	13.37%	5.49%	5/1/2025 (Estimated)
MYGN Myriad Genetics	-$263.30M	-$1.41	N/A	N/A	N/A	-14.09%	-4.51%	-3.07%	5/6/2025 (Estimated)
NTRA Natera	-$434.80M	-$1.53	N/A	N/A	N/A	-14.01%	-26.23%	-14.27%	5/8/2025 (Estimated)

Latest ILMN, NTRA, EXAS, MYGN, and AZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	AZN AstraZeneca	$1.10	N/A	N/A	N/A	N/A	N/A
2/27/2025	Q4 2024	NTRA Natera	-$0.42	-$0.41	+$0.01	-$0.41	$447.91 million	$476.10 million
2/25/2025	Q4 2024	MYGN Myriad Genetics	$0.03	-$0.09	-$0.12	-$0.47	$210.35 million	$210.60 million
2/19/2025	Q4 2024	EXAS Exact Sciences	-$0.29	-$0.06	+$0.23	-$4.67	$701.45 million	$713.42 million
2/6/2025	Q4 2024	AZN AstraZeneca	$1.10	$1.05	-$0.05	$0.48	$14.19 billion	N/A
2/6/2025	Q4 2024	ILMN Illumina	$0.92	$0.86	-$0.06	$1.17	$1.08 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	2.80%	+1.98%	91.15%	N/A
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
ILMN Illumina	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A

Latest ILMN, NTRA, EXAS, MYGN, and AZN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2025	AZN AstraZeneca	semi-annual	$1.03	2%	2/21/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.93	0.74
EXAS Exact Sciences	0.97	2.15	1.93
ILMN Illumina	0.63	1.77	1.42
MYGN Myriad Genetics	0.05	1.90	1.73
NTRA Natera	0.33	4.39	4.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
EXAS Exact Sciences	88.82%
ILMN Illumina	89.42%
MYGN Myriad Genetics	99.02%
NTRA Natera	99.90%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
EXAS Exact Sciences	1.36%
ILMN Illumina	0.17%
MYGN Myriad Genetics	2.10%
NTRA Natera	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
EXAS Exact Sciences	6,400	185.76 million	182.56 million	Optionable
ILMN Illumina	9,030	158.40 million	158.13 million	Optionable
MYGN Myriad Genetics	2,700	91.31 million	89.12 million	Optionable
NTRA Natera	3,020	135.19 million	121.99 million	Optionable

ILMN, NTRA, EXAS, MYGN, and AZN Headlines

Recent News About These Companies

Norges Bank Makes New Investment in Natera, Inc. (NASDAQ:NTRA)

April 1 at 4:23 AM | marketbeat.com

IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases 1,910 Shares of Natera, Inc. (NASDAQ:NTRA)

March 30 at 5:25 AM | marketbeat.com

Loomis Sayles & Co. L P Lowers Position in Natera, Inc. (NASDAQ:NTRA)

March 29 at 5:46 AM | marketbeat.com

JPMorgan Chase & Co. Raises Holdings in Natera, Inc. (NASDAQ:NTRA)

March 29 at 5:30 AM | marketbeat.com

Natera, Inc. (NASDAQ:NTRA) is Eagle Health Investments LP's Largest Position

March 28, 2025 | marketbeat.com

4,000 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by Sava Infond d.o.o.

March 28, 2025 | marketbeat.com

Vanguard Group Inc. Has $1.95 Billion Stake in Natera, Inc. (NASDAQ:NTRA)

March 28, 2025 | marketbeat.com

11,644 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Banco BTG Pactual S.A.

March 27, 2025 | marketbeat.com

23,800 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by KLP Kapitalforvaltning AS

March 27, 2025 | marketbeat.com

Quantbot Technologies LP Buys Shares of 5,546 Natera, Inc. (NASDAQ:NTRA)

March 27, 2025 | marketbeat.com

EFG Asset Management North America Corp. Sells 9,323 Shares of Natera, Inc. (NASDAQ:NTRA)

March 26, 2025 | marketbeat.com

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

March 25, 2025 | standard-journal.com

Zevenbergen Capital Investments LLC Trims Holdings in Natera, Inc. (NASDAQ:NTRA)

March 25, 2025 | marketbeat.com

Perkins Capital Management Inc. Sells 3,675 Shares of Natera, Inc. (NASDAQ:NTRA)

March 25, 2025 | marketbeat.com

Cannon Global Investment Management LLC Purchases New Stake in Natera, Inc. (NASDAQ:NTRA)

March 25, 2025 | marketbeat.com

Sei Investments Co. Decreases Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

March 25, 2025 | marketbeat.com

Is Natera, Inc. (NTRA) the Best Diagnostics Stock to Invest in Right Now?

March 24, 2025 | insidermonkey.com

American Century Companies Inc. Has $157.57 Million Stake in Natera, Inc. (NASDAQ:NTRA)

March 24, 2025 | marketbeat.com

Natera, Inc. (NASDAQ:NTRA) Stake Raised by Teacher Retirement System of Texas

March 24, 2025 | marketbeat.com

Thrivent Financial for Lutherans Reduces Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

March 23, 2025 | marketbeat.com

Envestnet Portfolio Solutions Inc. Trims Stock Position in Natera, Inc. (NASDAQ:NTRA)

March 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Palantir Bears Sell the Headlines—Time for Bulls to Buy?
By Chris Markoch | March 7, 2025
View Palantir Bears Sell the Headlines—Time for Bulls to Buy?
Tariffs Won’t Stop These 3 Stocks From Rising
By Chris Markoch | March 5, 2025
View Tariffs Won’t Stop These 3 Stocks From Rising
5 Reasons Oracle Is Undervalued and Ready to Rebound
By Thomas Hughes | March 20, 2025
View 5 Reasons Oracle Is Undervalued and Ready to Rebound
3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow Margins
By Leo Miller | March 19, 2025
View 3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow Margins
Gold Breaks $3,000: What's Driving the Rally and How to Invest?
By Ryan Hasson | March 17, 2025
View Gold Breaks $3,000: What's Driving the Rally and How to Invest?

ILMN, NTRA, EXAS, MYGN, and AZN Company Descriptions

AstraZeneca NASDAQ:AZN

$73.50 -0.29 (-0.39%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$73.89 +0.39 (+0.52%)

As of 09:02 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Exact Sciences NASDAQ:EXAS

$43.29 -0.37 (-0.85%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$43.88 +0.59 (+1.35%)

As of 08:57 AM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Illumina NASDAQ:ILMN

$79.34 -0.66 (-0.83%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$79.20 -0.14 (-0.18%)

As of 08:56 AM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Myriad Genetics NASDAQ:MYGN

$8.87 -0.01 (-0.11%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$8.55 -0.32 (-3.61%)

As of 08:38 AM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Natera NASDAQ:NTRA

$141.41 -2.53 (-1.76%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$140.24 -1.16 (-0.82%)

As of 08:52 AM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ILMN, NTRA, EXAS, MYGN, and AZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ILMN, NTRA, EXAS, MYGN, and AZN Earnings

Compare Dividends

Latest ILMN, NTRA, EXAS, MYGN, and AZN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ILMN, NTRA, EXAS, MYGN, and AZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ILMN, NTRA, EXAS, MYGN, and AZN Company Descriptions

AstraZeneca NASDAQ:AZN

Exact Sciences NASDAQ:EXAS

Illumina NASDAQ:ILMN

Myriad Genetics NASDAQ:MYGN

Natera NASDAQ:NTRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools